Biogen Idec's first-quarter profits jumped 50 percent to $244 million on higher sales of its multiple sclerosis drug Avonex; revenues grew by a healthy 10 percent to $1.04 billon, and EPS beat analysts' estimates. Report [1]
Links:
[1] http://www.boston.com/business/articles/2009/04/17/ms_drug_boosts_biogen_idec_profit_50/